For example, patients with more pronounced volume overload, stronger activation of the renin–angiotensin–aldosterone system, or those with specific comorbidities (e.g., diabetic nephropathy or HF) might derive a greater antihypertensive benefit [9, 19, 20]. The gene discussed is REN; the disease is hydrops fetalis.